Renal oncocytoma is one of the most common benign renal neoplasms, accounting for around 3–7% of all renal tumours, and up to 18% of all small renal masses (SRMs) measuring less than 4cm [1, 2]. Most oncocytomas are asymptomatic and...
Azur Innovation recently launched PQtap, a mobile application designed to support the home monitoring of a range of urology conditions. The app is available on Apple’s App Store and Google Play and may be recommended by healthcare professionals to patients...
Who was Stauffer and what is Stauffer’s syndrome? Maurice Stauffer (1915-1994) was a gastroenterologist at the Mayo Clinic in Rochester, United States, and in 1961 first characterised the non-metastatic, paraneoplastic effects of renal cell carcinoma (RCC) on liver size and...
Look out for part 2 of this series later in 2016 when the author will discuss settling into the research role of his fellowship and will reflect on his first year overseas. This is the first in a series of...
What is a leadership fellowship?” This is a question that is often asked about my year out of training to undertake the National Medical Director’s (NMD) Clinical Fellow Scheme. I hope to provide an insight into what a fellowship in...
As per Cochrane definition (2013), a systematic literature review (SR) attempts “to identify, appraise and synthesize all the empirical evidence that meets pre-specified eligibility criteria to answer a given research question” [1]. A meta-analysis (MA) is a statistical assessment of...
The market for bladder outflow obstruction surgery is currently wide open with new technologies such as Urolift® emerging. One of the key selling points of new technologies is the comparative safety and efficacy compared to traditional techniques such as transurethral...
Renal oncocytomas are the second most common benign renal tumours and they originate from the collecting tubules. They appear genotypically very similar to chromophobe renal cell carcinomas (chRCC), which also contain eosinophilic cells. Oncocytomas are often found incidentally on routine...
Alternatives to the standard transurethral resection of the prostate (TURP) in the management of bladder outflow obstruction due to prostatic hypertrophy are becoming more common. In this retrospective case series, the outcomes of 117 patients undergoing GreenLightTM lithium triborate photoselective...
In recent years laparascopic partial nephrectomy (LPN) has emerged as an oncologically safe alternative to its radical nephrectomy counterpart. There is however a lack of consensus amongst the urology community regarding surveillance after LPN for patients with stage I tumours....
Over recent years there has been a massive uptake in robotic surgery particularly for robot-assisted prostatectomy. The drive for this has been patient and physician led with little in the way of prospective randomised trials showing benefits over established operative...
Bladder cancer (BC) after radical nephroureterectomy (RNU) has an approximate incidence of 20-50%. This contemporary multicentre study will inform the ongoing debate on risk factors for BC after minimally invasive RNU and how it may be prevented. Three hundred and...